Probiotics and microbial metabolites maintain barrier and neuromuscular functions and clean protein aggregation to delay disease progression in TDP43 mutation mice

References

• Sonawane AR, Tian L, Chu CY, Qiu X, Wang L, Holden-Wiltse J, Grier A, Gill SR, Caserta MT, Falsey AR. et al. Microbiome-Transcriptome Interactions related to severity of respiratory syncytial virus infection. Sci Rep. 2019;9(1):13824. doi:10.1038/s41598-019-50217-w.
   PubMedGoogle Scholar
• Martin S, Battistini C, Sun J. A gut feeling in amyotrophic lateral sclerosis: microbiome of mice and men. Front Cell Infect Microbiol. 2022;12:839526. doi:10.3389/fcimb.2022.839526.
   PubMed Web of Science ®Google Scholar
• Zhang YG, Ogbu D, Garrett S, Xia Y, Sun J. Aberrant enteric neuromuscular system and dysbiosis in amyotrophic lateral sclerosis. bioRxiv 2021:2021.07.13.452097.Gut Microbes. 2021;13(1). doi:10.1080/19490976.2021.1996848.
   Web of Science ®Google Scholar
• Y RJ, Jung B, Sun J. Gut inflammation and dysbiosis in human motor neuron disease. Physiol Rep. 2017;Manuscript ID:HY2–2017–07–24.
   Google Scholar
• Blacher E, Bashiardes S, Shapiro H, Rothschild D, Mor U, Dori-Bachash M, Kleimeyer C, Moresi C, Harnik Y, Zur M. et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature. 2019;572(7770):474–480. doi:10.1038/s41586-019-1443-5.
   PubMed Web of Science ®Google Scholar
• Bhattacharjee S, Lukiw WJ. Alzheimer’s disease and the microbiome. Front Cell Neurosci. 2013;7:153. doi:10.3389/fncel.2013.00153.
   PubMed Web of Science ®Google Scholar
• Chandra S, Sisodia SS, Vassar RJ. The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored. Mol Neurodegener. 2023;18(1):9. doi:10.1186/s13024-023-00595-7.
   PubMed Web of Science ®Google Scholar
• Chen C, Liao J, Xia Y, Liu X, Jones R, Haran J, McCormick B, Sampson TR, Alam A, Ye K. et al. Gut microbiota regulate Alzheimer’s disease pathologies and cognitive disorders via PUFA-associated neuroinflammation. Gut. 2022;71(11):gutjnl-2021–326269. doi:10.1136/gutjnl-2021-326269.
   Web of Science ®Google Scholar
• Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, Challis C, Schretter CE, Rocha S, Gradinaru V. et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of parkinson’s disease. Cell. 2016;167(6):1469–80 e12. doi:10.1016/j.cell.2016.11.018.
   PubMed Web of Science ®Google Scholar
• Hsiao EY, McBride SW, Hsien S, Sharon G, Hyde ER, McCue T, Codelli J, Chow J, Reisman S, Petrosino J. et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013;155(7):1451–1463. doi:10.1016/j.cell.2013.11.024.
   PubMed Web of Science ®Google Scholar
• Zhang YG, Wu S, Yi J, Xia Y, Jin D, Zhou J, Sun J. Target intestinal microbiota to alleviate disease progression in amyotrophic lateral sclerosis. Clin Ther. 2017;39(2):322–336. doi:10.1016/j.clinthera.2016.12.014.
   PubMed Web of Science ®Google Scholar
• Wu S, Yi J, Zhang YG, Zhou J, Sun J. Leaky intestine and impaired microbiome in an amyotrophic lateral sclerosis mouse model. Physiol Rep. 2015;3(4):3. doi:10.14814/phy2.12356.
   Google Scholar
• Zhang Y, Ogbu D, Garrett S, Xia Y, Sun J. Aberrant enteric neuromuscular system and dysbiosis in amyotrophic lateral sclerosis. Gut Microbes. 2021;13(1):1996848. doi:10.1080/19490976.2021.1996848.
   PubMed Web of Science ®Google Scholar
• Arseni D, Hasegawa M, Murzin AG, Kametani F, Arai M, Yoshida M, Ryskeldi-Falcon B. Structure of pathological TDP-43 filaments from ALS with FTLD. Nature. 2022;601(7891):139–143. doi:10.1038/s41586-021-04199-3.
   PubMed Web of Science ®Google Scholar
• Hatzipetros T, Bogdanik LP, Tassinari VR, Kidd JD, Moreno AJ, Davis C, Osborne M, Austin A, Vieira FG, Lutz C. et al. C57BL/6J congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus of the colon without exhibiting key features of ALS. Brain Res. 2014;1584:59–72. doi:10.1016/j.brainres.2013.10.013.
   PubMed Web of Science ®Google Scholar
• Zhang YG, Lu R, Xia Y, Zhou D, Petrof E, Claud EC, Sun J. Lack of vitamin d receptor leads to hyperfunction of Claudin-2 in Intestinal inflammatory responses. Inflamm Bowel Dis. 2018;25:97–110. doi:10.1093/ibd/izy292.
   Web of Science ®Google Scholar
• Zhang Y, Garrett S, Carroll RE, Xia Y, Sun J. Vitamin D receptor upregulates tight junction protein claudin-5 against colitis-associated tumorigenesis. Mucosal Immunol. 2022;15(4):683–697. doi:10.1038/s41385-022-00502-1.
   PubMed Web of Science ®Google Scholar
• Amini S, White MK. Neuronal cell culture : methods and protocols. (NY): Humana Press; 2013.
   Google Scholar
• Smith TH, Ngwainmbi J, Grider JR, Dewey WL, Akbarali HI. An in-vitro preparation of isolated enteric neurons and glia from the myenteric plexus of the adult mouse. J Vis Exp. 2013;(78). doi:10.3791/50688.
   Web of Science ®Google Scholar
• Wang Z, Ocadiz-Ruiz R, Sundaresan S, Ding L, Hayes M, Sahoo N, Xu H, Merchant JL. Isolation of enteric glial cells from the submucosa and lamina propria of the adult mouse. Jove-J Vis Exp. 2018;(138). doi:10.3791/57629.
   Web of Science ®Google Scholar
• Toepfer M, Folwaczny C, Klauser A, Riepl RL, Muller-Felber W, Pongratz D. Gastrointestinal dysfunction in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 1999;1(1):15–19. doi:10.1080/146608299300079484.
   PubMed Web of Science ®Google Scholar
• Oprisan AL, Popescu BO. Dysautonomia in amyotrophic lateral sclerosis. Int J Mol Sci. 2023;24(19):24. doi:10.3390/ijms241914927.
   Web of Science ®Google Scholar
• Bianco F, Lattanzio G, Lorenzini L, Diquigiovanni C, Mazzoni M, Clavenzani P, Calzà L, Giardino L, Sternini C, Bonora E. et al. Novel understanding on genetic mechanisms of enteric neuropathies leading to severe gut dysmotility. Eur J Histochem. 2021;65(s1):65. doi:10.4081/ejh.2021.3289.
   Google Scholar
• Stephenson LA, Haney LB, Hussaini IM, Karns LR, Glass WF. Regulation of smooth muscle α-actin expression and hypertrophy in cultured mesangial cells. Kidney Int. 1998 2nd. 54(4):1175–1187. doi:10.1046/j.1523-1755.1998.00101.x.
   PubMed Web of Science ®Google Scholar
• Jaynes E, Carr NJ, Bateman AC. Deranged smooth muscle -actin expression as a biomarker of intestinal pseudo-obstruction. Gut. 2005;54(9):1346. doi:10.1136/gut.2004.062307.
   PubMed Web of Science ®Google Scholar
• Verde F, Milone I, Maranzano A, Colombo E, Torre S, Solca F, Doretti A, Gentile F, Manini A, Bonetti R. et al. Serum levels of glial fibrillary acidic protein in patients with amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2023;10(1):118–129. doi:10.1002/acn3.51708.
   PubMed Web of Science ®Google Scholar
• Agah E, Saleh F, Sanjari Moghaddam H, Saghazadeh A, Tafakhori A, Rezaei N. CSF and blood biomarkers in amyotrophic lateral sclerosis: protocol for a systematic review and meta-analysis. Syst Rev. 2018;7(1):237. doi:10.1186/s13643-018-0913-4.
   PubMedGoogle Scholar
• El Mendili MM, Querin G, Bede P, Pradat PF. Spinal cord imaging in amyotrophic lateral sclerosis: historical concepts-novel techniques. Front Neurol. 2019;10:350. doi:10.3389/fneur.2019.00350.
   PubMed Web of Science ®Google Scholar
• Jia W, Lu R, Martin TA, Jiang WG. The role of claudin-5 in blood-brain barrier (BBB) and brain metastases (review). Mol Med Rep. 2014;9(3):779–785. doi:10.3892/mmr.2013.1875.
   PubMed Web of Science ®Google Scholar
• Greene C, Hanley N, Campbell M. Claudin-5: gatekeeper of neurological function. Fluids Barriers CNS. 2019;16(1):3. doi:10.1186/s12987-019-0123-z.
   PubMed Web of Science ®Google Scholar
• Meister S, Storck SE, Hameister E, Behl C, Weggen S, Clement AM, Pietrzik CU. Expression of the ALS-Causing Variant hSOD1 G93A leads to an impaired integrity and altered regulation of Claudin-5 expression in an in vitro blood–spinal cord barrier model. J Cereb Blood Flow Metab. 2015;35(7):1112–1121. doi:10.1038/jcbfm.2015.57.
   PubMed Web of Science ®Google Scholar
• Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood–brain barrier: structure, regulation, and drug delivery. Sig Transduct Target Ther. 2023;8:217. doi:10.1038/s41392-023-01481-w.
   PubMed Web of Science ®Google Scholar
• Lochhead JJ, Yang J, Ronaldson PT, Structure DT. Function, and regulation of the blood-brain barrier tight junction in central nervous system disorders. Front Physiol. 2020;11:914. doi:10.3389/fphys.2020.00914.
   PubMed Web of Science ®Google Scholar
• Kakaroubas N, Brennan S, Keon M, Saksena NK. Pathomechanisms of blood-brain barrier disruption in ALS. Neurosci J. 2019;2019:2537698. doi:10.1155/2019/2537698.
   PubMedGoogle Scholar
• Steinruecke M, Lonergan RM, Selvaraj BT, Chandran S, Diaz-Castro B, Stavrou M. Blood-CNS barrier dysfunction in amyotrophic lateral sclerosis: proposed mechanisms and clinical implications. J Cereb Blood Flow Metab. 2023;43(5):642–654. doi:10.1177/0271678X231153281.
   PubMed Web of Science ®Google Scholar
• You S, Ma Y, Yan B, Pei W, Wu Q, Ding C, Huang C. The promotion mechanism of prebiotics for probiotics: a review. Front Nutr. 2022;9:1000517. doi:10.3389/fnut.2022.1000517.
   PubMed Web of Science ®Google Scholar
• Amara AA, Shibl A. Role of Probiotics in health improvement, infection control and disease treatment and management. Saudi Pharm J. 2015;23(2):107–114. doi:10.1016/j.jsps.2013.07.001.
   PubMed Web of Science ®Google Scholar
• Cheng FS, Pan D, Chang B, Jiang M, Sang LX. Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases. World J Clin Cases. 2020;8(8):1361–1384. doi:10.12998/wjcc.v8.i8.1361.
   PubMed Web of Science ®Google Scholar
• Detman A, Mielecki D, Chojnacka A, Salamon A, Blaszczyk MK, Sikora A. Cell factories converting lactate and acetate to butyrate: clostridium butyricum and microbial communities from dark fermentation bioreactors. Microb Cell Fact. 2019;18(1):36. doi:10.1186/s12934-019-1085-1.
   PubMedGoogle Scholar
• Deleu S, Machiels K, Raes J, Verbeke K, Vermeire S. Short chain fatty acids and its producing organisms: an overlooked therapy for IBD? EBioMedicine. 2021;66:103293. doi:10.1016/j.ebiom.2021.103293.
   PubMed Web of Science ®Google Scholar
• Ohkawara S, Furuya H, Nagashima K, Asanuma N, Hino T. Effect of oral administration of butyrivibrio fibrisolvens MDT-1 on experimental enterocolitis in mice. Clin Vaccine Immunol. 2006;13(11):1231–1236. doi:10.1128/CVI.00267-06.
   PubMedGoogle Scholar
• Effenberger M, Reider S, Waschina S, Bronowski C, Enrich B, Adolph TE, Koch R, Moschen AR, Rosenstiel P, Aden K. et al. Microbial butyrate synthesis indicates therapeutic efficacy of azathioprine in IBD patients. J Crohns Colitis. 2021;15(1):88–98. doi:10.1093/ecco-jcc/jjaa152.
   PubMed Web of Science ®Google Scholar
• Wexler HM. Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev. 2007;20(4):593–621. doi:10.1128/CMR.00008-07.
   PubMed Web of Science ®Google Scholar
• Hill CA, Casterline BW, Valguarnera E, Hecht AL, Shepherd ES, Sonnenburg JL, Bubeck Wardenburg J. Bacteroides fragilis toxin expression enables lamina propria niche acquisition in the developing mouse gut. Nat Microbiol. 2024;9(1):85–94. doi:10.1038/s41564-023-01559-9.
   PubMedGoogle Scholar
• Tortelli R, Zecca C, Piccininni M, Benmahamed S, Dell’abate MT, Barulli MR, Capozzo R, Battista P, Logroscino G. Plasma Inflammatory Cytokines Are Elevated in ALS. Front Neurol. 2020;11:552295. doi:10.3389/fneur.2020.552295.
   PubMed Web of Science ®Google Scholar
• Staats KA, Borchelt DR, Tansey MG, Wymer J. Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis. Mol Neurodegener. 2022;17(1):11. doi:10.1186/s13024-022-00515-1.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Wang Z, Wei X, Yu XF. Inflammatory checkpoints in amyotrophic lateral sclerosis: from biomarkers to therapeutic targets. Front Immunol. 2022;13:1059994. doi:10.3389/fimmu.2022.1059994.
   PubMed Web of Science ®Google Scholar
• Cao MC, Cawston EE, Chen G, Brooks C, Douwes J, McLean D, Graham ES, Dragunow M, Scotter EL. Serum biomarkers of neuroinflammation and blood-brain barrier leakage in amyotrophic lateral sclerosis. BMC Neurol. 2022;22(1):216. doi:10.1186/s12883-022-02730-1.
   PubMed Web of Science ®Google Scholar
• Zhang R, Miller RG, Gascon R, Champion S, Katz J, Lancero M, Narvaez A, Honrada R, Ruvalcaba D, McGrath MS. et al. Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol. 2009;206(1–2):121–124. doi:10.1016/j.jneuroim.2008.09.017.
   PubMed Web of Science ®Google Scholar
• Ogbu D, Zhang Y, Claud K, Xia Y, Sun J. Target metabolites to slow down progression of amyotrophic lateral sclerosis in mice. Metabolites. 2022;12(12):12. doi:10.3390/metabo12121253.
   Web of Science ®Google Scholar
• Pattle SB, O’Shaughnessy J, Kantelberg O, Rifai OM, Pate J, Nellany K, Hays N, Arends MJ, Horrocks MH, Waldron FM. et al. pTDP-43 aggregates accumulate in non-central nervous system tissues prior to symptom onset in amyotrophic lateral sclerosis: a case series linking archival surgical biopsies with clinical phenotypic data. J Pathol Clin Res. 2023;9(1):44–55. doi:10.1002/cjp2.297.
   PubMedGoogle Scholar
• Berning BA, Walker AK. The pathobiology of TDP-43 C-Terminal fragments in ALS and FTLD. Front Neurosci. 2019;13:335. doi:10.3389/fnins.2019.00335.
   PubMed Web of Science ®Google Scholar
• Shenouda M, Xiao S, MacNair L, Lau A, Robertson J. A C-Terminally Truncated TDP-43 splice isoform exhibits neuronal specific cytoplasmic aggregation and contributes to TDP-43 Pathology in ALS. Front Neurosci. 2022;16:868556. doi:10.3389/fnins.2022.868556.
   PubMed Web of Science ®Google Scholar
• Cykowski MD, Powell SZ, Appel JW, Arumanayagam AS, Rivera AL, Appel SH. Phosphorylated TDP-43 (pTDP-43) aggregates in the axial skeletal muscle of patients with sporadic and familial amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2018;6(1):28. doi:10.1186/s40478-018-0528-y.
   PubMed Web of Science ®Google Scholar
• Keating SS, Bademosi AT, San Gil R, Walker AK. Aggregation-prone TDP-43 sequesters and drives pathological transitions of free nuclear TDP-43. Cell Mol Life Sci. 2023;80(4):95. doi:10.1007/s00018-023-04739-2.
   PubMed Web of Science ®Google Scholar
• Ohsawa K, Imai Y, Sasaki Y, Kohsaka S. Microglia/macrophage-specific protein Iba1 binds to fimbrin and enhances its actin-bundling activity. J Neurochem. 2004;88(4):844–856. doi:10.1046/j.1471-4159.2003.02213.x.
   PubMed Web of Science ®Google Scholar
• Hopperton KE, Mohammad D, Trepanier MO, Giuliano V, Bazinet RP. Markers of microglia in post-mortem brain samples from patients with Alzheimer’s disease: a systematic review. Mol Psychiatry. 2018;23(2):177–198. doi:10.1038/mp.2017.246.
   PubMed Web of Science ®Google Scholar
• Chen S, Cai X, Lao L, Wang Y, Su H, Sun H. Brain-gut-microbiota axis in amyotrophic lateral sclerosis: A historical overview and future directions. Aging Dis. 2024;15(1):74–95. doi:10.14336/AD.2023.0524.
   PubMed Web of Science ®Google Scholar
• Dora D, Ferenczi S, Stavely R, Toth VE, Varga ZV, Kovacs T, Bodi I, Hotta R, Kovacs KJ, Goldstein AM. et al. Evidence of a myenteric plexus barrier and its macrophage-dependent degradation during murine colitis: implications in enteric neuroinflammation. Cell Mol Gastroenterol Hepatol. 2021;12(5):1617–1641. doi:10.1016/j.jcmgh.2021.07.003.
   PubMed Web of Science ®Google Scholar
• Jerico I, Vicuna-Urriza J, Blanco-Luquin I, Macias M, Martinez-Merino L, Roldan M, Rojas-Garcia R, Pagola-Lorz I, Carbayo A, De Luna N. et al. Profiling TREM2 expression in amyotrophic lateral sclerosis. Brain Behav Immun. 2023;109:117–126. doi:10.1016/j.bbi.2023.01.013.
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Toledo JB, Van Deerlin VM, Elman L, McCluskey L, Lee VM, Trojanowski JQ. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS One. 2012;7(6):e39216. doi:10.1371/journal.pone.0039216.
   PubMed Web of Science ®Google Scholar
• Al-Obaidi MMJ, Desa MNM. Mechanisms of blood brain barrier disruption by different types of bacteria, and bacterial–host interactions facilitate the bacterial pathogen invading the brain. Cell Mol Neurobiol. 2018;38(7):1349–1368. doi:10.1007/s10571-018-0609-2.
   PubMed Web of Science ®Google Scholar
• Kniesel U, Wolburg H. Tight junctions of the blood-brain barrier. Cell Mol Neurobiol. 2000;20(1):57–76. doi:10.1023/A:1006995910836.
   PubMed Web of Science ®Google Scholar
• Ouali Alami N, Tang L, Wiesner D, Commisso B, Bayer D, Weishaupt J, Dupuis L, Wong P, Baumann B, Wirth T. et al. Multiplexed chemogenetics in astrocytes and motoneurons restore blood–spinal cord barrier in ALS. Life Sci Alliance. 2020;3(11):3. doi:10.26508/lsa.201900571.
   Web of Science ®Google Scholar
• Distrutti E, O’Reilly JA, McDonald C, Cipriani S, Renga B, Lynch MA, Fiorucci S. Modulation of intestinal microbiota by the probiotic VSL#3 resets brain gene expression and ameliorates the age-related deficit in LTP. PLoS One. 2014;9(9):e106503. doi:10.1371/journal.pone.0106503.
   PubMed Web of Science ®Google Scholar
• Beard JD, Kamel F. Military service, deployments, and exposures in relation to amyotrophic lateral sclerosis etiology and survival. Epidemiol Rev. 2015;37(1):55–70. doi:10.1093/epirev/mxu001.
   PubMed Web of Science ®Google Scholar
• Labarre A, Guitard E, Tossing G, Forest A, Bareke E, Labrecque M, Tétreault M, Ruiz M, Alex Parker J. Fatty acids derived from the probiotic Lacticaseibacillus rhamnosus HA-114 suppress age-dependent neurodegeneration. Commun Biol. 2022;5(1):1340. doi:10.1038/s42003-022-04295-8.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, Karam C, Caress JB, Owegi MA, Quick A. et al. Trial of sodium phenylbutyrate–taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919–930. doi:10.1056/NEJMoa1916945.
   PubMed Web of Science ®Google Scholar
• Sitkin S, Vakhitov T, Pokrotnieks J. How to increase the butyrate-producing capacity of the gut microbiome: do IBD patients really need butyrate replacement and butyrogenic therapy? J Crohn’s And Colitis. 2018;12:881–882. doi:10.1093/ecco-jcc/jjy033.
   PubMed Web of Science ®Google Scholar
• Sitkin S, Vakhitov T, Pokrotnieks J. Oral butyrate modulates the gut microbiota in patients with inflammatory bowel disease, most likely by reversing proinflammatory metabolic reprogramming of colonocytes. Neurogastroenterol Motil. 2021;33(1):e14038. doi:10.1111/nmo.14038.
   PubMed Web of Science ®Google Scholar
• Roth W, Zadeh K, Vekariya R, Ge Y, Mohamadzadeh M. Tryptophan metabolism and gut-brain homeostasis. Int J Mol Sci. 2021;22(6):22. doi:10.3390/ijms22062973.
   Web of Science ®Google Scholar
• Tan G VX, Guillemin, Gj GJ. Kynurenine pathway metabolites as biomarkers for amyotrophic lateral sclerosis. Front Neurosci. 2019;13:1013. doi:10.3389/fnins.2019.01013.
   PubMed Web of Science ®Google Scholar